2 Beaten-Down Stocks to Avoid Right Now

Intellia Therapeutics and Sarepta Therapeutics have faced significant clinical setbacks, leading to increased investment risk and market value depreciation. Intellia paused trials for its gene-editing candidate nexiguran ziclumeran following a patient death from liver damage, while Sarepta reported multiple patient deaths from acute liver failure across its gene therapies, including its commercialized Elevidys, resulting in a 15% Q3 revenue decline and anticipated label restrictions. These incidents highlight the inherent volatility and risks in clinical-stage biotech, particularly in gene therapy, making both companies currently unattractive for investment despite their lower valuations.

Analysis

Intellia Therapeutics (NTLA) faces significant clinical risk following the pause of its nexiguran ziclumeran (nex-z) clinical trials due to a patient death from liver damage. This incident underscores the inherent volatility and potential side effects associated with gene-editing therapies, despite nex-z targeting an area of high unmet medical need. The company, however, maintains a strong cash position of $670 million, sufficient to fund operations until mid-2027, and benefits from a partnership with Regeneron Pharmaceuticals.

Sarepta Therapeutics (SRPT) has also encountered severe setbacks, reporting multiple patient deaths from acute liver failure linked to its gene therapies, including the commercialized Elevidys. This has directly impacted financial performance, with Q3 revenue declining 15% year-over-year to $399.4 million and a non-GAAP net loss per share of $0.13, compared to a $0.64 EPS profit in the prior year. Regulatory discussions are expected to result in a restricted label for Elevidys, further limiting its sales potential.

The recurrence of acute liver failure across different gene therapies and companies, including a third patient death in a now-discontinued Sarepta trial, highlights systemic safety concerns within the gene therapy sector. Both companies' stock prices have plummeted, reflecting a "strongly negative" sentiment (-0.8 score) and increased investment risk. While gene therapies offer curative potential, these events emphasize the substantial clinical and regulatory hurdles that can severely impact commercial viability and investor confidence.

Key Decisions for Investors

• Investors should maintain a cautious stance on both Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT) given the severe clinical setbacks and regulatory uncertainties.
• Monitor regulatory outcomes for nex-z and Elevidys, specifically any label restrictions or trial holds, as these will directly impact future revenue potential and risk profiles.
• Consider the broader implications for the gene therapy sector, as these events may lead to increased regulatory scrutiny and a re-evaluation of risk premiums for clinical-stage biotechs.